186 related articles for article (PubMed ID: 15221296)
1. 99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer.
Mena E; Camacho V; Estorch M; Fuertes J; Flotats A; Carrió I
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1399-404. PubMed ID: 15221296
[TBL] [Abstract][Full Text] [Related]
2. Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer.
Axelsson R; Herlin G; Bååth M; Aspelin P; Kölbeck KG
Acta Radiol; 2008 Apr; 49(3):295-302. PubMed ID: 18365818
[TBL] [Abstract][Full Text] [Related]
3. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.
Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C
Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172
[TBL] [Abstract][Full Text] [Related]
4. Imaging of regional lymph node metastases with 99mTc-depreotide in patients with lung cancer.
Danielsson R; Bååth M; Svensson L; Forslöv U; Kölbeck KG
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):925-31. PubMed ID: 15841374
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy with 99mTc-Depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study.
Bååth M; Kölbeck KG; Danielsson R
Acta Radiol; 2004 Dec; 45(8):833-9. PubMed ID: 15690613
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
Nucl Med Rev Cent East Eur; 2006; 9(1):24-9. PubMed ID: 16791800
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of 99mTc-depreotide uptake in patients with non-small-cell lung cancer: immunohistochemical correlations.
Herlin G; Kölbeck KG; Menzel PL; Svensson L; Aspelin P; Capitanio A; Axelsson R
Acta Radiol; 2009 Oct; 50(8):902-8. PubMed ID: 19707908
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-depreotide scintigraphy in the evaluation of indeterminate pulmonary lesions: clinical experience.
Martins T; Lino JS; Ramos S; Oliveira L
Cancer Biother Radiopharm; 2004 Apr; 19(2):253-9. PubMed ID: 15186606
[TBL] [Abstract][Full Text] [Related]
9. [Fusion of pulmonary scintigraphy with Tc99m-depreotide imaging with CT scan in recognizing solitary pulmonary nodule].
Szaluś N; Chciałowski A; From S; Zagrodzka M; Pietrzykowski J; Dziuk E
Pol Merkur Lekarski; 2008 Oct; 25(148):330-4. PubMed ID: 19145931
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-depreotide in the evaluation of bone infection and inflammation.
Papathanasiou ND; Rondogianni PE; Pianou NK; Karampina PA; Vlontzou EA; Datseris IE
Nucl Med Commun; 2008 Mar; 29(3):239-46. PubMed ID: 18349794
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules.
Grewal RK; Dadparvar S; Yu JQ; Babaria CJ; Cavanaugh T; Sherman M; Jacobstein J
Cancer J; 2002; 8(5):400-4. PubMed ID: 12416898
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and staging of children's lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide.
Cholewinski W; Kowalczyk JR; Stefaniak B; Stefaniak J; Poniatowicz-Frasunek E; Tarkowska A
Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):820-4. PubMed ID: 14762697
[TBL] [Abstract][Full Text] [Related]
13. Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules.
Halley A; Hugentobler A; Icard P; Porret E; Sobrio F; Lerochais JP; Bouvard G; Zalcman G; Agostini D
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1026-32. PubMed ID: 15877227
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of 99mTc-depreotide and 201Tl chloride single photon emission tomography in the characterization of pulmonary lesions.
Boundas D; Karatzas N; Moralidis E; Arsos G; Drevelengas A; Pistevou-Gompaki K; Karakatsanis C
Nucl Med Commun; 2007 Jul; 28(7):533-40. PubMed ID: 17538394
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy.
Van Den Bossche B; Van Belle S; De Winter F; Signore A; Van de Wiele C
J Nucl Med; 2006 Jan; 47(1):6-13. PubMed ID: 16391181
[TBL] [Abstract][Full Text] [Related]
16. Bone metastases and lung cancer recurrence on (99m)Tc-depreotide imaging.
Meristoudis G; Ilias I; Batsakis C; Christakopoulou J
Hell J Nucl Med; 2008; 11(3):185-6, author reply 186. PubMed ID: 19081868
[No Abstract] [Full Text] [Related]
17. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer.
Rodrigues M; Li S; Gabriel M; Heute D; Greifeneder M; Virgolini I
J Clin Endocrinol Metab; 2006 Oct; 91(10):3997-4000. PubMed ID: 16895961
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma.
Bushnell DL; Menda Y; Madsen MT; Link BK; Kahn D; Truhlar SM; Juweid M; Shannon M; Murguia JS
Nucl Med Commun; 2004 Aug; 25(8):839-43. PubMed ID: 15266180
[TBL] [Abstract][Full Text] [Related]
19. Uptake of depreotide in a patient with lung cancer and bone metastases.
Gao Z; Biersack HJ; Bucerius J
Clin Nucl Med; 2005 Jan; 30(1):60-1. PubMed ID: 15604979
[No Abstract] [Full Text] [Related]
20. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
